Plasma apixaban concentrations and thrombin generation assay parameters in response to dose reduction for atrial fibrillation.
Muhan YeoSo-Ryoung LeeEue-Keun ChoiJungMin ChoiKyung-Yeon LeeHyo-Jeong AhnSoonil KwonHyoung-Seob ParkHyun Kyung KimSeil OhGregory Y H LipPublished in: British journal of clinical pharmacology (2024)
Off-label underdosed apixaban resulted in lower apixaban concentrations than both on-label standard and reduced-dose regimens. A considerable proportion of the patients exhibited apixaban concentrations outside the expected range, suggesting the potential benefits of plasma concentration monitoring. Further studies are needed to compare dosages directly, investigate the impact of plasma apixaban concentration monitoring and validate the current dose-reduction criteria.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- oral anticoagulants
- left atrial
- direct oral anticoagulants
- catheter ablation
- left atrial appendage
- end stage renal disease
- heart failure
- newly diagnosed
- ejection fraction
- percutaneous coronary intervention
- chronic kidney disease
- high throughput
- prognostic factors
- patient reported outcomes
- peritoneal dialysis
- coronary artery disease
- left ventricular
- single cell
- mitral valve